The 10th anniversary of the introduction of Ropixon® was grandly commemorated on Thursday, April 16 (Farvardin 28), at the Espinas Palace Hotel in Tehran. Attended by a distinguished assembly of cardiologists and medical experts, the event highlighted the drug’s decade-long impact on patient care.

During his keynote address, Eng. Nima Bararjanian, CEO of Cobel Group, emphasized the organization’s core mission: “At Dr. Abidi Pharmaceuticals, we are continuously striving to sustain innovation in the cardiovascular field and other therapeutic areas by manufacturing high-quality products based on novel molecules.” He described this strategic approach as a monumental step toward more effective disease management and the reduction of national mortality rates.

A Legacy of Impact and Future Innovations

Opening the event, Mr. Bararjanian reflected on the profound responsibility of Dr. Abidi Pharmaceuticals in maintaining rigorous drug quality standards, proudly noting that the company’s medications have aided in the treatment of approximately 7 million patients suffering from chronic diseases.

“Our ongoing commitment to controlling cardiovascular diseases—which account for one of the highest mortality rates in the country—remains a primary objective for Cobel Group,” the CEO stated. Furthermore, he announced upcoming milestones driven by the research-driven and knowledge-based enterprises within the Group, revealing: “By the end of this year, we will officially unveil our newest therapeutic solution, Ropixon-Plus®.”

Expert Cardiology Panel: The Clinical Value of Statins

Following the CEO’s address, a specialized clinical panel was convened, moderated by Dr. Seyed Hashem Sezavar, a prominent Cardiologist. The panel featured esteemed specialists including Dr. Mojtaba Malek, Dr. Vahid Eslami, and Dr. Adel Jahed. The robust scientific discussion covered critical topics, including:

– The historical evolution and clinical impact of Statins.

– Identifying patient demographics that derive the most significant benefits from statin therapy.

– The absolute necessity of statin administration in patients with Type 2 Diabetes (T2D).

– Sharing the latest global clinical trials and research findings in lipid management.

The Hidden World of Commitment to Quality

In the concluding segment of the ceremony, Dr. Ronak Saadati, Senior Manager of Quality Excellence at Cobel Group, delivered a compelling presentation titled “The Hidden World of Commitment to Quality”—shedding light on the meticulous processes that occur away from the public eye.

Highlighting the highly systematic, strictly controlled, and transparent nature of the drug quality evaluation system, Dr. Saadati remarked: “In a world full of uncertainties, we rigorously control every factor that impacts quality. Backed by profound scientific knowledge and our unwavering commitment to excellence, we hold absolute confidence in our products.”

She further emphasized that maintaining pharmaceutical quality goes beyond the product itself, identifying human resources as the foundational pillar in the Quality Assurance (QA) cycle. “Motivated, highly capable, and exceptionally trained colleagues consistently execute their responsibilities flawlessly. We also ensure absolute occupational safety, guaranteeing that our personnel are never adversely exposed to pharmaceutical chemicals, while simultaneously upholding environmental sustainability and ensuring no harm comes to the ecosystem.”

About Ropixon®: A Vital Therapeutic Solution by Dr. Abidi Pharmaceuticals

Ropixon®, classified as a lipid-lowering agent, plays a paramount role in the primary and secondary prevention of cardiovascular diseases.

During the event, Dr. Adel Jahed presented compelling epidemiological data: According to the latest global statistics, there are currently 650 million diabetic patients worldwide. In Iran, diabetes is directly responsible for 8% to 13% of all mortalities, with projections indicating a continued upward trajectory. Amidst these escalating figures, Ropixon® continues to stand out as a life-saving medication for diabetic and cardiovascular patients.